Named after the Ukrainian word for stork - a timeless symbol of new beginnings - Leleka Bio is on a mission to bring new life to oncology drug discovery. In a landscape where over 90% of cancer drugs fail in clinical trials, we’re building the infrastructure that links real patient biology to AI-powered prediction, enabling faster, more reliable therapeutic development. With every tumor model, digital twin, and validated prediction, we bring the promise of precision medicine closer to reality.
About Leleka Bio
Leleka Bio is an upcoming predictive oncology platform built on real human biology. We are in the process of integrating high-quality patient-derived 3D tumor models with cutting-edge AI to simulate drug response and resistance before clinical trials. Unlike AI-first drug discovery platforms that rely on synthetic or public datasets, Leleka Bio will ground its insights in fresh patient tumors, capturing clinically relevant phenotypes and omics data.
Platform Components & Features
Patient-Derived 3D Tumor Models (Available Now)
Fresh tumor-derived, non-immortalized 3D cultures Models maintain original architecture and heterogeneity Available across high-burden cancer types Ethically sourced with matched clinical metadata
Multi-Omics Profiling Services (Available Now)
Transcriptomics, proteomics, and mutational profiling Tumor microenvironment characterization Cell type deconvolution & immune mapping
Leleka BI™ Digital Twin Engine (In Development)
AI-powered prediction of tumor drug response Integrates biological features (gene/protein expression, mutations) with clinical metadata Simulates resistance patterns and highlights patient stratification opportunities
Bioprinted Synthetic Tumor Models (Pending)
In partnership with Frontier Bio Designed to enable in vivo-like validation without animal models Scalable and reproducible for pharma pilot integration
Secure Client Portal & PaaS Interface (Roadmap)
In partnership with Frontier Bio Designed to enable in vivo-like validation without animal models Scalable and reproducible for pharma pilot integration
We strive to empower scientists with AI-driven insights from real tumors—to accelerate discovery, reduce failure, and bring better therapies to patients faster.
Leleka Bio will provide pharmaceutical and biotech teams with:
Fresh patient-derived tumor models Ethically sourced and expanded in 3D
Multi-modal data outputs Histology, transcriptomics, mutational landscape, and drug response
Planned digital twins AI-driven tumor-specific simulators in development to predict therapy outcomes
Why It Matters Traditional models (cell lines, PDXs) fail to represent human tumor heterogeneity. AI alone can't compensate for poor biological input. Leleka Bio aims to become the first platform that fully integrates tissue, tech, and therapeutic testing.
🔄 Customer Value
For R&D Teams: Prioritize leads with higher likelihood of clinical success. Validate targets on human-relevant models. Identify resistance early and guide combination therapy development.
For Translational & Biomarker Teams: Correlate model response with patient stratification markers. Develop and test companion diagnostics preclinically
For AI & Data Teams: Access deeply annotated, high-quality biological training sets. Use digital twin predictions to complement internal algorithms
Release Dates
Q4 2025: Alpha release of Leleka BI™ predictive modules
Q1 2026: Beta access to secure client portal
Mid 2026: Integration of bioprinted tumor model catalog
Leleka Bio is being developed by DRL, a next-generation oncology CRO with the diverse patient tumor biobank. We are backed by experience, guided by science, and powered by innovation.
Contract research organization, which provides solutions for pharma and diagnostics companies, including consulting, cancer models development, and various assays for drug development.
